Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105599 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of the FairCare System for Patients With Advanced Illness
A Phase 2 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT00105599: Completed Phase 2 study, sponsored by US Department of Veterans Affairs.
NCT00105599 is a Phase 2 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 140 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00105599, a Phase 2 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study of the FairCare Program (FC) is designed to address end of life (EOL) care delivery issues by reducing barriers to effective EOL care among health care providers, family members, surrogates, and Chronic Heart Failure (CHF) patients using a comprehensive, multi-pronged approach delivered by a care coordinator and supported by an interdisciplinary team.
Interventions
- BEHAVIORAL End of life care coordination
- PROCEDURE FairCare System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
What the finished NCT00105599 record still lists
NCT00105599 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which End of life care coordination is the first listed.
NCT00105599 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00105599 about?
NCT00105599 is a clinical study titled "Effectiveness of the FairCare System for Patients With Advanced Illness". This study of the FairCare Program (FC) is designed to address end of life (EOL) care delivery issues by reducing barriers to effective EOL care among health care providers, family members, surrogates, and Chronic Heart Failure (CHF) patients using a comprehensive, multi-pronged approach delivered b...
What is the current status of trial NCT00105599?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00105599?
The interventions under investigation include: End of life care coordination (BEHAVIORAL), FairCare System (PROCEDURE).
Who is sponsoring clinical trial NCT00105599?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00105599's enrollment target sits among peer trials
140 512th of 2000 higher than 1,476 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia